ArticleFrontiers in immunology2026
Next-generation single-cycle respiratory syncytial virus vaccines with increased type I interferon induction yield robust systemic and mucosal responses in mice.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously demonstrated that vaccination with RSV-Mnull, a prototype single-cycle live vaccine lacking the matrix (M) gene, generated anti-viral serum IgG and memory T cell responses, and reduced challenge virus shedding and pulmonary dysfunction in mice. Here we further characterized the response to RSV-Mnull, and designed and tested second generation Mnull vaccines. In mice, prime-boost vaccination with RSV-Mnull generated pre-fusion (preF) and attachment protein (G) -specific serum IgG and lung IgA, and protected from lung pathology, showing that a single-cycle live vaccine was effective in this model. In an effort to enhance efficacy for future human application, second generation Mnull vaccines were designed, in which nonstructural protein 1 (NS1), a known interferon (IFN) antagonist, was relocated to reduce expression. In addition, the G or F genes were moved to the first genome position (RSV-Mnull/G1 and RSV-Mnull/F1 respectively).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.